Eight pre-selected start-ups from medicine and life sciences pitched their business ideas at the 13th BioAngels Pitch Day hosted by BioM, the network organization of the Bavarian biotechnology. In just 12 minutes, founders presented scientific data and corporate strategy to a selected audience of investors who specialize in life science and healthcare technologies. This bi-annual matchmaking event once again showcased innovative ideas in the fields of drug development, digital health and medical technology.
The business ideas were wide-ranging. Eight teams presented innovative solutions to challenges in the laboratory/healthcare sector as well as new therapy options for hard-to-treat cancers and respiratory diseases.
In advance, BioM prepared the founders in a training one week prior to the Pitch Day. With the BioM team, the start-up teams and an external expert offered each other feedback in a collaborative workshop format. The aim was to present the business model and scientific data succinctly. Equipped with new feedback, the teams went home and optimized their pitches. As a result, the teams were well prepared for the vetting questions of the invited investors following their pitches.
Benjamin Winkeljann from RNhale explained: “When you’re practicing your pitch on your own, you’re creating for yourself. But when you’re in a room with people with different background and experiences, you’re introduced to new perspectives that can really elevate your pitch.” Rnhale aims to develop a platform technology for formulating RNA-loaded lipid nanoparticles (LNPs) as an inhalable dry powder.
The Dymium team was delighted to have the opportunity to present their idea to an audience eager to invest. “The BioM BioAngels event is a great opportunity to meet investors when you’re actively fundraising," said Florian Ebel. The company, which was awarded the BioRegions Innovation Award in 2021, has developed a technology that makes it possible to reliably remove even the smallest fragments of kidney stones.
The BioM BioAngels Pitch event was once again very well received by investors.
Paul Sunzenauer of OCCIDENT offered his perspective: "We find that BioM is a quality source for deals. As a deeptech investor, it is difficult to find unique and promising early-stage prospects. It’s necessary for us to have a relationship with BioM to find these companies."
As part of its diverse start-up support program, BioM helps bioentrepreneurs connect with potential investors in the biomedical field through matchmaking events.
The teams who presented at the BioAngels Pitch Day 2024 and their ideas:
Dymium – Reducing the global recurrence of kidney stones.
The Dymium Magnetic Retrieval System revolutionizes kidney stone surgery, minimizing recurrence risk for patients and delivering highest quality treatment in shorter operation time.
Elexion Medical – Fight care shortage with digitization of patient monitoring.
Elexion Medical helps fight the care shortage and improve patient outcome in hospitals and nursing homes by automated monitoring of patients’ fluid lines with SaaS, AI and enabling IoT devices.
RNhale – The Next Generation of Inhalable RNA Therapeutics.
RNhale is a spin-off originating from the LMU Munich, aiming to revolutionize the pharmaceutical landscape by developing a unique platform technology for formulating RNA-loaded lipid nanoparticles (LNPs) as an inhalable dry powder. This disruptive approach synergizes technological and pharmaceutical strategies to create a novel therapeutic formulation with significant advantages over common LNP-RNA delivery methods.
Deep Piction – Intelligence in Medicine.
Deep Piction’s unique technology platform enables it to provide experimental and AI services to assess drug effects in large 3D samples and to become a major player in AI-driven drug development.
UniteLabs – The Lab 4.0 Platform.
UniteLabs is an integration platform for lab automation that connects hard- & software across vendor barriers to digitalise life science R&D.
XO Life – Provide every patient with digital product and treatment companion.
XO Life aims to build the biggest and best global patient platform for high quality patient knowledge, real world patient data, patient exchange and support in everyday care. Today, patients usually turn to Dr. Google, Facebook, Insta and Co. for research and exchange because there is no reasonable highly attractive patient platform.
PRAMOMOLECULAR – Silencing Cancer.
PRAMOMOLECULAR is silencing cancer proteins: no cancer protein – no tumour growth.
AATec Medical – New accessible and affordable therapeutics for globally increasing respiratory diseases.
AATec Medical is a new biotech Munich-based startup developing new therapies for inflammatory diseases and viral infections of the airways. Target indications are acute respiratory distress syndrome (ARDS), respiratory viral infections and severe allergic asthma.
www.bio-m.org
https://www.linkedin.com/company/biom-gmbh
https://www.youtube.com/BioMTV
The business ideas were wide-ranging. Eight teams presented innovative solutions to challenges in the laboratory/healthcare sector as well as new therapy options for hard-to-treat cancers and respiratory diseases.
In advance, BioM prepared the founders in a training one week prior to the Pitch Day. With the BioM team, the start-up teams and an external expert offered each other feedback in a collaborative workshop format. The aim was to present the business model and scientific data succinctly. Equipped with new feedback, the teams went home and optimized their pitches. As a result, the teams were well prepared for the vetting questions of the invited investors following their pitches.
Benjamin Winkeljann from RNhale explained: “When you’re practicing your pitch on your own, you’re creating for yourself. But when you’re in a room with people with different background and experiences, you’re introduced to new perspectives that can really elevate your pitch.” Rnhale aims to develop a platform technology for formulating RNA-loaded lipid nanoparticles (LNPs) as an inhalable dry powder.
The Dymium team was delighted to have the opportunity to present their idea to an audience eager to invest. “The BioM BioAngels event is a great opportunity to meet investors when you’re actively fundraising," said Florian Ebel. The company, which was awarded the BioRegions Innovation Award in 2021, has developed a technology that makes it possible to reliably remove even the smallest fragments of kidney stones.
The BioM BioAngels Pitch event was once again very well received by investors.
Paul Sunzenauer of OCCIDENT offered his perspective: "We find that BioM is a quality source for deals. As a deeptech investor, it is difficult to find unique and promising early-stage prospects. It’s necessary for us to have a relationship with BioM to find these companies."
As part of its diverse start-up support program, BioM helps bioentrepreneurs connect with potential investors in the biomedical field through matchmaking events.
The teams who presented at the BioAngels Pitch Day 2024 and their ideas:
Dymium – Reducing the global recurrence of kidney stones.
The Dymium Magnetic Retrieval System revolutionizes kidney stone surgery, minimizing recurrence risk for patients and delivering highest quality treatment in shorter operation time.
Elexion Medical – Fight care shortage with digitization of patient monitoring.
Elexion Medical helps fight the care shortage and improve patient outcome in hospitals and nursing homes by automated monitoring of patients’ fluid lines with SaaS, AI and enabling IoT devices.
RNhale – The Next Generation of Inhalable RNA Therapeutics.
RNhale is a spin-off originating from the LMU Munich, aiming to revolutionize the pharmaceutical landscape by developing a unique platform technology for formulating RNA-loaded lipid nanoparticles (LNPs) as an inhalable dry powder. This disruptive approach synergizes technological and pharmaceutical strategies to create a novel therapeutic formulation with significant advantages over common LNP-RNA delivery methods.
Deep Piction – Intelligence in Medicine.
Deep Piction’s unique technology platform enables it to provide experimental and AI services to assess drug effects in large 3D samples and to become a major player in AI-driven drug development.
UniteLabs – The Lab 4.0 Platform.
UniteLabs is an integration platform for lab automation that connects hard- & software across vendor barriers to digitalise life science R&D.
XO Life – Provide every patient with digital product and treatment companion.
XO Life aims to build the biggest and best global patient platform for high quality patient knowledge, real world patient data, patient exchange and support in everyday care. Today, patients usually turn to Dr. Google, Facebook, Insta and Co. for research and exchange because there is no reasonable highly attractive patient platform.
PRAMOMOLECULAR – Silencing Cancer.
PRAMOMOLECULAR is silencing cancer proteins: no cancer protein – no tumour growth.
AATec Medical – New accessible and affordable therapeutics for globally increasing respiratory diseases.
AATec Medical is a new biotech Munich-based startup developing new therapies for inflammatory diseases and viral infections of the airways. Target indications are acute respiratory distress syndrome (ARDS), respiratory viral infections and severe allergic asthma.
www.bio-m.org
https://www.linkedin.com/company/biom-gmbh
https://www.youtube.com/BioMTV
